Immune to Cancer: The CRI Blog




Patient Immunotherapy Summit: Breast Cancer Brief

While one in eight women in the U.S. will develop breast cancer in their lifetime, the good news is that the cancer has an 89% five-year survival outlook. CRI is proud to have Sarah Sammons, MD, the Associate Director of the Metastatic Breast Cancer Program at the Dana-Farber Cancer Institute, further discuss this important type of cancer. Dr. Sammons seeks to improve outcomes for breast cancer patients, particularly for those experiencing the complications of breast cancer metastasis.

Read more:

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.